The human endocrine system is a complex network of glands and organs that release hormones, acting as chemical messengers in the body. These hormones regulate distant target organs, such as the stomach and liver. Endocrine therapy, also known as hormone therapy, involves manipulating the hormones to treat various conditions like diabetes, breast cancer, postmenopausal symptoms, and contraception. This therapy focuses on either blocking or enhancing the action of specific hormones or the organs that produce them. Aromatase inhibitors like anastrozole, exemestane, and letrozole reduce estrogen synthesis by inhibiting the aromatase enzyme. Selective estrogen receptor modulators (SERMs) like toremifene and tamoxifen, as well as selective estrogen receptor degraders (SERDs) like fulvestrant, directly target the estrogen receptor.
The global market for endocrine therapy drugs (ETDs) is projected to grow due to the rising prevalence of chronic illnesses like breast cancer and diabetes. Research and development efforts in developing new ETDs for treating these diseases are also contributing to the market's growth. Furthermore, key market players are actively seeking approval for their ETD applications, further propelling the market's expansion.
In 2022, the global market for Endocrine Therapy Drugs (ETDs) is projected to reach a value of US$ 28,958.4 million, with a predicted compound annual growth rate (CAGR) of 5.1% during the forecast period of 2022 to 2030.
Major Players in the Endocrine Theraphy Drug Industry:
- Novo Nordisk A/S
Novo Nordisk was established in 1923 and is headquartered in Bagsværd, Denmark. It operates in over 170 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals. In 2021, Novo Nordisk announced that the US Food and Drug Administration (FDA) had approved Wegovy™.
- Pfizer Inc.
Pfizer Inc. was established in 1849 and is headquartered in New York, United States. It operates in 181 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals. In 2021, Pfizer Inc. received U.S. Food and Drug Administration (FDA) approval for their supplement new drug application for MYFEMBREE, an endocrine therapy drug for pain management associated with endometriosis.
- AstraZeneca
AstraZeneca was established in 1999 and is headquartered in Cambridge, United Kingdom. It operates in over 100 countries and is engaged in various industries, including biopharma, biotechnology, healthcare, medical, and pharmaceutical. In 2022, AstraZeneca announced that two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancer.
- Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. was established in 1944 and is headquartered in Tel Aviv, Israel. It has operations in 60 countries and is engaged in various industries, including biopharma, healthcare, medical, and pharmaceuticals.
- Hoffmann-La Roche
Hoffmann-La Roche Ltd. was established in 1896 and is headquartered in Basel, Switzerland. It operates in over 100 countries and is engaged in various industries, including biotechnology, healthcare, health diagnostics, and pharmaceuticals.
- Merck & Co., Inc.
Merck & Co. was established in 1891 and is headquartered in Rahway, New Jersey, United States. It operates in over 191 countries and is engaged in developing medicines, vaccines, biologic therapies, and animal health products.
- Amgen Inc.
Amgen Inc. was established in 1980 and is headquartered in Thousand Oaks, California, in the United States. It operates in nearly 100 countries and is engaged in various industries, including biotechnology, healthcare, and pharmaceutical manufacturing.
- Abbott
Abbott Laboratories was established in 1888 and is headquartered in Chicago, Illinois, United States. It operates in 24 countries and is engaged in the manufacturing of medical devices, pharmaceuticals, diagnostics, and nutritional products.
Definition: Endocrine therapy is a treatment that uses hormones or hormone-blocking drugs to slow or stop the growth of hormone-sensitive cancers.
